Oncology News and Research

RSS
Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Women & Infants Hospital awarded $5 million NIH grant to support COBRE for Perinatal Biology

Women & Infants Hospital awarded $5 million NIH grant to support COBRE for Perinatal Biology

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

AbbVie selects Halozyme's ENHANZE platform to augment their development pipeline

El Camino Hospital enrolls first patient in safety study using RenovoCath

El Camino Hospital enrolls first patient in safety study using RenovoCath

Mary's Place by the Sea - helping women with cancer

Mary's Place by the Sea - helping women with cancer

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

New article published in Spanish Journal of Pathology highlights a rare case of Hodgkin's lymphoma

New article published in Spanish Journal of Pathology highlights a rare case of Hodgkin's lymphoma

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

Genentech, Seragon, Regeneron and Avalanche receive Allicense 2015 Breakthrough Award for Deals of the Year

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

Survey shows most men with advanced prostate cancer ignore their symptoms as disease progresses

Majority of breast cancer patients unaware of the effect of double mastectomy

Majority of breast cancer patients unaware of the effect of double mastectomy

NCCN ORP and Pfizer IGLC collaborate to improve lives of people with metastatic breast cancer

NCCN ORP and Pfizer IGLC collaborate to improve lives of people with metastatic breast cancer

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

MorphoSys' MOR202 proprietary drug candidate meets primary endpoints in multiple myeloma patients

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

Celldex’s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.